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Abstract
Stevens–Johnson syndrome and toxic epidermal necrolysis are rare
severe blistering skin reactions triggered by medications or infections.
Over the last 5 to 10 years, a number of important publications have
advanced understanding of these diseases and their response to
treatment. Importantly, a subset of patients with disease triggered by
infection has been identified as having Mycoplasma
pneumoniae–induced rash and mucositis, suggesting a
reconsideration of the diagnostic paradigm. We present an update on
pediatric Stevens–Johnson syndrome and toxic epidermal necrolysis in
the broader context of cutaneous adverse drug reactions and focus
on challenges and recent advances in diagnosis, management, and
prevention.
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Introduction

and metabolically mediated) (Table 1). cADRs can be
classified clinically by morphology and severity on the basis of
the presence (complex) or absence (simple) of fever and other
systemic symptoms (Table 2).

Skin (cutaneous) reactions are among the most common types
of adverse reactions to medications in children, accounting
for 36% of any adverse drug reaction (ADR)1. Many of these
reactions are mild and self-resolving, but the rare severe
ADRs can be associated with significant morbidity and even
mortality. The diagnosis and treatment of cutaneous ADRs
(cADRs) in children are challenging for several reasons. First,
children are more commonly infected with viruses as compared with adults; each year, children in their first years of
life average six to 10 respiratory viral infections and older children and adolescents average three to five such illnesses2.
Many of these viruses, such as Epstein–Barr virus, adenovirus,
and enteroviruses, are frequently associated with cutaneous
reactions that can be misinterpreted as cADRs. Second,
triggers of severe cADRs, such as Stevens–Johnson syndrome (SJS), are different in adults and children; medications
more often are implicated in adults and infections more commonly cause SJS in children3. Third, causality tools currently
available—for example, Naranjo, algorithm of drug causality for epidermal necrolysis (ALDEN), and the US Food and
Drug Administration’s division of drug experience—have
been developed and studied primarily in adults and not applied
to children. Finally, owing to the overall rarity of severe
cADRs in children, there is little evidence to guide treatment.

Given their rarity, complex or severe cADRs are difficult to
study systematically and pediatric-specific data are limited.
These challenges have led to the adoption of adult paradigms
for diagnosis and management in pediatric practice, where
better evidence exists.
In SJS and toxic epidermal necrolysis (TEN), severe blistering
of the skin and mucous membranes related to either
medications or infections occurs. The differential diagnosis in
early cases where diffuse erythema is common may include
viral exanthems, Kawasaki disease, and acute generalized
exanthematous pustulosis. As widespread blistering begins
to develop, thermal burns, toxic erythema of chemotherapy,
pemphigus of all types, staphylococcal scalded skin syndrome
(which spares the mucous membranes), acute graft-versus-host
disease, acute syndrome of apoptotic pan-epidermolysis associated with systemic lupus erythematosus, and generalized
bullous fixed drug eruption become the primary considerations.
In recent years, significant developments have occurred
in the category of severe blistering drug reactions—SJS
and TEN—the focus of this review. The watershed evolutions
in this area will be reviewed and ultimately support the need

ADRs can be either type A (predictable, caused by on-target
drug action) or type B (heterogeneous, immunologically

Table 1. Cutaneous adverse drug reactions mechanisms summary.
Type A - Augmented

Type B - Bizarre

Predictable (example:
overdose)

Non-immunological Immunological
(example:
Type I: IgE
intolerance)

Type II: IgG Type III: immune Type IV: delayed
cytotoxic
complexes
hypersensitivity

Urticaria/Angioedema

Hemolytic
anemia

Vasculitis

Delayed
IVa: ACD
IVb: DiHS/DRESS
IVc: SJS-TEN, morbilliform
IVd: AGEP

ACD, allergic contact dermatitis; AGEP, acute generalized exanthematous pustulosis; DiHS, drug-induced hypersensitivity syndrome; DRESS, drug
reaction with eosinophilia and systemic symptoms; SJS-TEN, Stevens–Johnson syndrome–toxic epidermal necrolysis4. Adapted with permission from
Noguera-Morel et al.1.

Table 2. Morphology and severity summary.
Exanthematous

Urticarial Blistering

Pustular

Simple – no fever

Morbilliform

Urticaria

FDE, SDRIFE

Acneiform

Complex – fever

Drug HSS/DRESS SSLR

SJS-TEN

AGEP

AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with
eosinophilia and systemic symptoms; FDE, fixed drug eruption; HSS, hypersensitivity
syndrome; SDRIFE, symmetrical drug related intertriginous and flexural exanthem;
SJS-TEN, Stevens–Johnson syndrome–toxic epidermal necrolysis; SSLR, serum sicknesslike reaction.5.
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for evolution of the diagnostic categories for severe blistering
cADRs in children.

Table 3. Severe blistering cutaneous adverse drug reactions
and Mycoplasma pneumoniae–induced rash and mucositis.

Incidence
Until 2017, estimates of the incidence of SJS and TEN were
based on retrospective surveys and databases from the 1990s
and a European registry6–9. More recently, larger datasets
have been used in attempts to better describe these rare events
in pediatrics.
A recent US pediatric database cohort study suggests that
SJS-TEN spectrum disorders occur in 7.5 per 100,000 hospitalized children10; incidences of 6.3 and 0.5 per 100,000 hospitalized
children per year for SJS and TEN, respectively, were reported.
A second US cross-sectional study that sourced data from
the same 2009–2012 time frame found much lower rates, of
5.3 (SJS) and 0.4 (TEN) per million children per year, in the
overall population11. Similar findings in both studies suggest
that pediatric SJS-TEN results in a substantial health-care
burden, although mortality is less when compared with adult
data. There are many limitations to using large datasets to
examine rare events such as SJS-TEN, including poor validity
of International Classification of Diseases 9/10 (ICD-9/10)
codes, inability to determine cause, and the lack of a standardized diagnostic approach across institutions. Given that
the clinical features of severe cADRs can be challenging to
interpret for diagnosis, standardization in case identification
and validation is needed.

Clinical features and refining diagnosis: drug versus
bug
Stevens–Johnson syndrome and toxic epidermal
necrolysis
SJS and TEN are characterized by blistering of the skin and
mucous membranes. One to three days before onset of skin
and mucosal lesions, prodromal symptoms start; these include
fever, general malaise, non-productive cough, stinging eyes,
and a sore mouth. These symptoms are often mistaken for
an upper respiratory tract infection. Macules with purpuric,
non-blanching centers with a predilection for the head and torso
evolve quickly, often within 12 hours, into blisters that
slough off, leaving large areas of denuded skin and mucosa.
Painful erythema of the palms and soles is also common
early in the disease. Target papules with three distinct rings, characteristic of erythema multiforme, a similar condition usually
triggered by herpes simplex virus12, are not the main morphology in SJS and TEN, although atypical two-ringed or macular
(flat) targets may occur early, before blistering starts. Mucosal
involvement affects oral, ocular, genitourinary, and anal sites.
SJS and TEN are believed to exist on a spectrum; there
is less than 10% body surface area (BSA) involvement in
SJS and greater than 30% BSA involvement in TEN, and
intermediate BSA involvement of 10 to 30% is called SJS-TEN
overlap (Table 3)13. Involved areas include skin that is already
blistered or detached and skin that is red (macular erythema)
and detachable.

Body surface area affected

SJS

SJS-TEN overlap TEN

<10%

10–30%

>30%

MIRM (usually <10% but can be
more extensive)
MIRM, Mycoplasma pneumoniae–induced rash and mucositis; SJS,
Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.

These diagnostic categories were developed in 1993 on the
basis of an expert review and synthesis of hundreds of adult
cases13, and for many pediatric cases, a diagnostic category can
be assigned. However, problems arise when patients have severe
involvement of their mucous membranes but little or no skin
lesions because there is no diagnostic category for them.

Mycoplasma pneumoniae–induced rash and mucositis
In 2015, Canavan et al.14 described Mycoplasma pneumoniae
(MP)-induced rash and mucositis (MIRM) as an entity distinct
from SJS. Patients with MIRM have exactly the features
of the previously noted patients who evaded classification;
they have severe mucositis of multiple mucous membranes out
of proportion to skin involvement, which typically is sparse
but in some cases may be significant14. The characteristic
constellation of features in MIRM is triggered by respiratory
infection rather than medications, and pathogens other than
MP have been reported15. Advances in technology, including
respiratory polymerase chain reaction (PCR), have improved
MP detection, and more specific methods to confirm infection have recently been developed16; these include measurement
of MP-specific antibody-secreting cells17.
The challenge with cases attributed to infection and with the
diagnosis of MIRM is that their clinical features overlap with
those of SJS, creating opportunities for patients to receive
multiple diagnoses and complicating more comprehensive
and systematic study of these cases in the future. Furthermore,
as there is no diagnostic code in the ICD-9 or ICD-10 for
MIRM, these patients would likely have been, and continue to
be, assigned codes for SJS, TEN, or erythema multiforme with
unreliable assignment with secondary codes for mycoplasma
infection.

Proposed revised classification
Author MLR is part of a group that recently proposed a revised
classification for severe blistering cutaneous reactions in
children; the revision condenses SJS and TEN into a single
category of drug-induced epidermal necrolysis (DEN) that may
have variable skin involvement (manuscript under revision). This
is logical because SJS and TEN are considered quantity variants of the same disease and drugs are their common trigger.
The proposed classification separates out the infection-related
cases typified by severe mucosal and less impressive skin
lesions as reactive infectious mucocutaneous eruption (RIME).
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Given their disparate causes and pathogeneses, DEN and
RIME have diverging management strategies: the focus is on
drug withdrawal and early consideration of immunosuppressive treatment in patients with DEN and on identification and
treatment of infection combined with supportive care with or
without immunosuppressive therapy in RIME cases. Application
of this novel pediatric-specific paradigm may have far-reaching
impacts on incidence and epidemiology and ultimately provide
more directed and effective management.

of drug exposure to reaction onset, the probability of drug
presence in the body, prior exposure to the same drug regardless
of reaction at that time, the presence of drug beyond the
progression phase, drug notoriety as an ADR cause, and the
presence or absence of other etiologies25. Although these
tools can be helpful, their usefulness is limited by variability
in results between users and testing methods. Further advancements in diagnostics and assessment tools have the potential
to enhance causality assessment in the future26.

Biomarkers will likely emerge as tools to confirm diagnosis; the granulysin rapid test, which has a turnaround time of
15 minutes, was used in a 2011 report to establish an early
diagnosis of SJS in a young child18. Other candidate biomarkers, including eosinophilia, perforin, interferon-gamma, soluble
Fas ligand, and CD69, are being evaluated, although none
is validated for clinical use at this time19.

Testing to identify the causative agent in SJS-TEN remains
controversial and is not widely used. In vivo (varied methods
of re-exposure of the patient to potential trigger medications)
testing includes patch testing or delayed intradermal testing. These tests can be performed once the acute reaction
has resolved but within a year. Potentially cross-reacting
medications can also be identified with patch testing27.
Unfortunately, the results are not reliable for all medications,
limiting their clinical utility. Oral re-challenge, recommended
for other types of drug reactions, is not recommended for SJS
and TEN given the serious risk of a second potentially fatal
episode28. In vitro testing with the lymphocyte transformation
test (LTT) during the recovery phase, 4 to 8 weeks after the
reaction, is controversial as LTT historically has had low
sensitivity in SJS-TEN and many false-positive and -negative
results29. Recent reports support better sensitivity (86%) and
specificity (74%) in SJS-TEN, even for low-risk drugs30. The
drug-specific interferon-gamma–releasing cell assay is highly
specific (95% specificity and 79% sensitivity for allopurinol)
and can be carried out in the acute phase31. A recent publication highlighted its advantages over LTT: higher rates of
causative drug identification (73.9% versus 52.2% for LTT) and
use during the acute phase (versus recovery phase for LTT)32.

Etiologies
Recent pediatric retrospective studies identify a drug as the cause
of SJS and TEN in 72 to 90% of cases20–23. Idiopathic cases,
where no cause (medication or infection) can be identified,
make up 5 to 17% of cases in retrospective reviews20,21,24.
A limited number of medications, including antibiotics, anticonvulsants, and non-steroidal anti-inflammatory drugs, are
implicated in the majority of pediatric cases. As stated above,
MP is a common trigger of severe mucocutaneous reactions
that have been considered SJS-TEN in the past; however,
the clinical presentation and outcomes suggest a unique
disease process.

Causality and risk reduction
It is important to avoid implicating medications used to
treat the prodromal symptoms of SJS and TEN as causative
agents19. Survivors of SJS and TEN are often told to avoid all
medications taken just prior to the reaction, limiting treatments
that can be used for future illnesses25 and causing patients and
families concern about the use of medications in general. Evaluation of possible implicated medications requires utilization
of an effective causality tool. Many available ADR causality
tools, including the Naranjo and Liverpool tools, are non-specific
to the ADR phenotype. The ALDEN is specific for severe
cADRs. These tools are helpful when considering the timing

Prevention of SJS and TEN is becoming a reality with the
identification of risk factors that can be screened prior to
drug initiation. Human leukocyte antigen (HLA) screening for ethnicity-specific risk alleles prior to administration of
aromatic anticonvulsants (including carbamazepine), allopurinol, and abacavir reduces the risk of SJS-TEN (Table 4)33.
Polymorphisms that reduce drug clearance can also increase
the risk of severe cADRs34 When a risk allele is identified
in a patient, the medication should be avoided35. As a proof

Table 4. Medication causes of SJS-TEN with strongly predictive (100%) HLA associations35.
Medication

Population

HLA
type

Interpretation of positive result

Allopurinol

Han Chinese and European

B*5801

Increased risk of SJS-TEN, do not use in naïve patients, can be
considered in patients without reaction after more than 3 months

Carbamazepine

Han Chinese, Thai, Malaysian,
Indian, Singaporean, and
Vietnamese

B*1502

Increased risk of SJS-TEN, do not use CBZ or ox-CBZ in naïve
patients, can consider using if no reaction after more than 3 months
treatment

European, Japanese, and Korean

B*3101

CBZ, carbamazepine; HLA, human leukocyte antigen; ox-CBZ, oxcarbazepine; SJS-TEN, Stevens–Johnson syndrome – toxic epidermal necrolysis.35.
Adapted with permission from Peter et al.19.
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of concept, in Taiwan, where pre-carbamazepine screening for HLA-B*1502 was adopted in 2010, the incidence
of SJS-TEN has drastically decreased36. In Thailand, where
HLA-B*1502 pre-treatment screening is also routine, HLA test
results are printed on a wallet card that patients can carry with
them as a “pharmacogenomic ID card” for future health-care
interactions35.

To treat or not to treat, that is the question… but we
still don’t know the answer
SCORe of Toxic Epidermal Necrolysis (SCORTEN), a TEN
severity-of-illness score37, was developed for adults but has
been used to predict both morbidity and mortality in pediatric
patients38,39. The SCORTEN has multiple factors, but three
of them—age of at least 40 years, malignancy, and heart
rate of at least 120 beats per minute—are less important in
children because (1) they are young, (2) they have low rates
of malignancy, and (3) their normal heart rate can be over
120 beats per minute if they are younger than four. The
SCORTEN, or a pediatric-adapted scoring system, could be
used prospectively in studies to predict treatment efficacy by
comparing actual with predicted mortality and morbidity38.
Despite the availability of a validated severity score that helps
to predict which patients will have more severe outcomes,
the absence of a gold-standard effective therapy for pediatric
SJS-TEN means that the decision between supportive care
and directed (immunosuppressive) therapy remains challenging.
In the last two years, there has been an explosion of retrospective and database publications on pediatric SJS-TEN
which have come to similar conclusions on the relative lack of
efficacy of corticosteroids and intravenous immunoglobulin
(IVIG) on various outcomes20,22,40–43. For treatment of SJS-TEN,
there is a consensus on the importance of rapid identification and withdrawal of the causative medication. As adjuvant
therapy, corticosteroids are most frequently used, followed
by IVIG both as monotherapy and in combination with
corticosteroids. None of these mono- or combination therapies
appears to affect time to healing or length of hospital stay. The
best evidence on treatment before 2017–2018 was from a large
(n = 128 cases) systematic review published in 2011 that
suggested that patients who received IVIG and prednisone had

better outcomes than those who received supportive care only44.
Overall mortality rates for SJS-TEN in newer publications
range from 0 to 6.6%, and rates of up to 25% were reported
for TEN cases20,22,40–43.
Recent case reports and case series document the rapid
efficacy of cyclosporine 3 mg/kg per day divided twice a day
and infliximab 5 mg/kg intravenously for one dose in both
drug- and infection-related cases45,46. There is emerging
evidence from case reports for anti-tumor necrosis factor
(anti-TNF) therapy in the acute phase47–50. Furthermore, a recent
Taiwanese randomized clinical trial of etanercept in TEN
included children older than 4 years of age and showed that
etanercept (25 mg twice weekly <65 kg and 50 mg if >65 kg)
decreased the predicted mortality rate and reduced skin healing time compared with corticosteroids (1 to 1.5 mg/kg per
day intravenously) in the group as a whole51. Both groups
received treatment until their skin lesions healed51. This study
included five children who were 6 to 13 years old51. Further
large-scale studies are needed to confirm these promising
results in the pediatric population.
Ocular complications and sequelae are significant for pediatric patients with SJS-TEN. Aggressive initial management,
including adjuvant amniotic membrane transplantation, can
reduce complications52,53. Even in the absence of severe
ocular involvement in acute SJS-TEN, children may develop
progressive disease of the ocular surface and conjunctival
inflammation over time54. Delayed lid margin keratinization55,
vision deterioration, and corneal damage can occur after
SJS-TEN56, emphasizing the importance of close continual
follow-up by ophthalmology55,57.
The early introduction of psychological and social support is critical for pediatric patients with SJS-TEN to avoid
long-term anxiety and depression. Ideally, the introduction
should occur as soon as the patient is stable enough for a psychologist or child-life worker to visit. For children, the experience
of complete loss of control of their body can be devastating,
and early explanation and attention to the patient’s emotional
needs are critical. Other chronic sequelae are summarized in
Table 5.

Table 5. Potential chronic sequelae of Stevens–Johnson syndrome – toxic epidermal necrolysis.
Organ system

Sequelae

Skin

Dyspigmentation, eruptive nevi, milia, nail dystrophy, alopecia, scarring, and heterotopic ossification

Ocular

Sicca symptoms, trichiasis, corneal vascularization, corneal scarring, symblepharon, keratitis, and blindness

Oral

Xerostomia, synechiae, chronic gingivitis, dental caries, periodontal disease, taste abnormalities, abnormal
dental development, and candidiasis

Gastrointestinal

Pancreatitis, colon necrosis, esophageal stenosis and webs, microstomia, and persistent intestinal ulcers

Genitourinary

Vaginal stenosis, labial fusion, hydrocolpos, hematocolpos, dyspareunia, vaginal dryness, and urethral stenosis

Pulmonary

Chronic obstructive bronchitis and bronchiolitis, bronchiectasis, and pharyngeal and laryngeal scarring

Autoimmune

Sjögren syndrome, systemic lupus erythematosus, and autoimmune thyroiditis

Psychiatric

Anxiety and depression

Adapted with permission from Peter et al.,19.
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Treatment of reactive infectious disease: Mycoplasma
pneumoniae and other infections
Given the limited data on reactive infectious mucocutaneous
eruptions, including MIRM and non-MP, it remains unclear
whether treatment should be similar to that of SJS-TEN. A
systematic review by Canavan et al. suggests that the majority
of patients receive antibiotics and a smaller percentage receive
corticosteroids, IVIGs, or supportive care only14. Although
antibiotics are used to treat MP respiratory infections, the
effect of antibiotics on the skin and mucous membrane
changes of MIRM is unclear14. Recurrent disease is reported
in up to 20% of patients23, suggesting a genetic susceptibility to reactive mucositis and rash which has yet to be
elucidated.
MP-related SJS-TEN overlap has been reported in one pediatric patient to have rapidly re-epithelialized with cyclosporine
3 mg/kg per day over a period of 7 days without co-treatment
for MP infection45. A second case report of TEN induced
by MP responded rapidly with complete resolution within a week
after a single dose of infliximab 5 mg/kg per day (the patient
also received meropenem)46. A case series of three children
whose MIRM was treated with cyclosporine suggests that the
addition of cyclosporine 3 to 5 mg/kg per day for early cases
may accelerate resolution compared with supportive care and
antibiotics alone58.
Generally, the course of MIRM is less severe than for
drug-related SJS-TEN, and supportive care is a reasonable option.
However, the mucous membranes should be closely monitored

as the same sequelae as are seen in SJS-TEN occur and can
be severe. A recent publication in the ophthalmology literature suggests that these children should be followed closely
during their inpatient admission similarly to SJS-TEN59. In
their systematic review, Canavan et al. reported ocular sequelae
in 9%, post-inflammatory dyspigmentation in 6%, and oral
or genital synechiae in less than 1%14. Severe gynecologic
sequelae requiring surgery have been reported60. Given the
sequelae and the acute severe disease course, psychosocial support should ideally be introduced to patients and families at
the time of diagnosis (as for SJS-TEN) and there should be a
regular review for signs of (latent) distress at follow-up visits to
their primary care provider.
The bottom line for therapy is that the identified triggering medication should be discontinued, an infection should be sought
and treated if suspected, supportive care in a low-ratio nursing environment should be provided, and anti-inflammatory
immunosuppressive therapy, particularly in the early acute
phase, should be considered. Specialist input should be sought
and coordinated. An overview of the approach to practical
management of pediatric SJS-TEN is presented in Table 6
and is detailed by McPherson et al.61.

How redefining diagnosis of pediatric Stevens–
Johnson syndrome – toxic epidermal necrolysis can
improve treatment
The literature on the treatment of pediatric SJS and TEN
is disappointing as larger studies suggest no impact of any
intervention other than drug withdrawal. In contrast, case

Table 6. Practical management of pediatric Stevens–Johnson syndrome – toxic epidermal necrolysis.
Admission

Determine cause based on drug history (ALDEN), infectious symptoms
Baseline:
Investigations: confirm cause, rule out contraindications to treatment
- routine bloodwork, including complete metabolic profile, liver function tests, urinalysis
- infectious workup, including viral serologies/PCR (Epstein–Barr virus, cytomegalovirus, HSV, human herpes virus 6),
nasopharyngeal swab for respiratory viruses and Mycoplasma pneumoniae PCR, oral mucosal swab for HSV PCR, chest
x-ray to rule out pneumonia
- screen for HLA risk alleles if not already known (Table 4)
- if patient severe and might need immunosuppression: consider interferon-gamma release assay for tuberculosis,
hepatitis and HIV serology, Strongyloides serology
Document severity: SCORTEN, BSA, photography
Treatment:
Discontinue potential causative medications
Treat for infection if present with directed antibiotics
Supportive care: sterile wound care, fluid replacement and nutritional supplementation as for burns, airway management,
pain control
Plan:
Assess need for transfer to specialized experienced center for severe cases (SCORTEN >1, BSA >10%, comorbidities,
requiring ventilation)
Consult dermatology, ophthalmology, gynecology, urology, infectious disease, pharmacy/clinical pharmacology urgently
Consider anti-inflammatory/immunosuppressive treatment: consider contraindications, risk-benefit

Monitoring

Frequent vital signs, monitor for fever
Frequent swabs to identify infection early, prophylactic antibiotics not recommended
Document progression with SCORTEN, photography
Supportive care, including early physiotherapy
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Follow-up

Identify a primary contact for the patient after discharge, either a pediatrician or specialist amongst the following:
    •    Dermatology
    •    Ophthalmology
    •    Gastroenterology
    •    Gynecology (female) and urology (male)
    •    Psychiatry/Psychology for post-traumatic stress disorder
    •    Genetics to review HLA testing and counsel family
    •    Respirology if needed
Consider in vitro testing with lymphocyte transformation test or ELISpot (controversial)
Give patient a wallet card that identifies their history of SJS-TEN and HLA screening result for future medical encounters.
Please refer to Figure 4 in Sukasem et al.35 for an example.

ALDEN, algorithm of drug causality for epidermal necrolysis; BSA, body surface area; HLA, human leukocyte antigen; HSV, herpes simplex virus; PCR,
polymerase chain reaction; SCORTEN, SCORe of Toxic Epidermal Necrolysis; SJS-TEN, Stevens–Johnson syndrome – toxic epidermal necrolysis.61,62.

series and reports document the effectiveness of various
anti-inflammatory immunosuppressive treatments. Could it be
that the way that past cases are classified results in groups that
are too heterogeneous (that is, triggered by infection or drugs or
idiopathic) to respond similarly to a given therapy? Considering a shift in diagnostic paradigm as discussed above may be
a way to interpret the existing literature with a lens focused
from cause/trigger to treatment. Adding to this a precision medicine approach that compares subpopulations of responders
with non-responders to identify characteristics that permit
early recognition and takes advantage of biomarkers like the
granulysin rapid test may lead to a future in which we can select
the right treatment for the right patient every time.

Conclusions
The future is bright for pediatric SJS-TEN. Initiatives are under
way to improve our understanding of this spectrum of disorders,
specifically in children. A British guideline on management

was recently published61. With increasing accessibility and
validation of risk factor screening (HLA and metabolism
variants) and biomarkers, we may soon be able to prevent
SJS-TEN in predisposed individuals and diagnose and treat it
early when it occurs by chance.

Abbreviations
ADR, adverse drug reaction; ALDEN, algorithm of drug causality for epidermal necrolysis; BSA, body surface area; cADR,
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